

DAFTAR PUSTAKA

1. Wright JM, Tekkesin MS. Odontogenic tumors: where are we in 2017? *J Istanbul Univ Fac Dent* 2017; 51: S10.
2. Effiom OA, Ogundana OM, Akinshipo AO, et al. Ameloblastoma: current etiopathological concepts and management. *Oral Dis* 2018; 24: 307–316.
3. MacDonald-Jankowski DS, Yeung R, Lee KM, et al. Ameloblastoma in the Hong Kong Chinese. Part 1: systematic review and clinical presentation. *Dentomaxillofacial Radiol* 2004; 33: 71–82.
4. Ruslin M, Hendra FN, Vojdani A, et al. The Epidemiology, treatment, and complication of ameloblastoma in East-Indonesia: 6 years retrospective study. *Med Oral Patol Oral Cir Bucal* 2018; 23: e54.
5. Yulvie W, Wijaya A, Handjari DR, et al. Demographic Variation of Ameloblastoma: A Retrospective Analysis of 188 Cases in the Indonesian Population. *J Int Dent Med Res* 2023; 16: 209–213.
6. Dhanuthai K, Chantarangsu S, Rojanawatsirivej S, et al. Ameloblastoma: a multicentric study. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2012; 113: 782–788.
7. Singh T, Wiesenfeld D, Clement J, et al. Ameloblastoma: demographic data and treatment outcomes from Melbourne, Australia. *Aust Dent J* 2015; 60: 24–29.
8. Li X, Zhu K, Liu F, et al. Assessment of quality of life in giant ameloblastoma adolescent patients who have had mandible defects reconstructed with a free fibula flap. *World J Surg Oncol* 2014; 12: 1–6.
9. Ooi A, Feng J, Tan HK, et al. Primary treatment of mandibular ameloblastoma with segmental resection and free fibula reconstruction: achieving satisfactory outcomes with low implant-prosthetic rehabilitation uptake. *J Plast Reconstr Aesthetic Surg* 2014; 67: 498–505.
10. Poedjiastoeti W, Ariesanti Y, Gunardi I, et al. Quality of Life in Post Ameloblastoma Treatment: A Meta-Analysis. *J Int Dent Med Res* 2023; 16: 367–376.
11. Dandriyal R, Gupta A, Pant S, et al. Surgical management of

- ameloblastoma: Conservative or radical approach. *Natl J Maxillofac Surg* 2011; 2: 22.
12. de AC Almeida R, Andrade ES de S, Barbalho JC, et al. Recurrence rate following treatment for primary multicystic ameloblastoma: systematic review and meta-analysis. *Int J Oral Maxillofac Surg* 2016; 45: 359–367.
 13. Pudiarifanti N, Pramantara ID, Ikawati Z. Faktor-faktor yang Mempengaruhi Kualitas Hidup Pasien Gagal Jantung Kronik. *J Manaj Dan Pelayanan Farm (Journal Manag Pharm Pract* 2015; 5: 259–266.
 14. Hamzah R, Widaryati W. Hubungan usia dan jenis kelamin dengan kualitas hidup pada penderita gagal jantung di RS PKU Muhammadiyah Yogyakarta.
 15. Barnes L, Eveson J, Reichart P, et al. World Health Organization classification of tumours: pathology and genetics of head and neck tumours.
 16. McClary AC, West RB, McClary AC, et al. Ameloblastoma: a clinical review and trends in management. *Eur Arch Oto-Rhino-Laryngology* 2016; 273: 1649–1661.
 17. Masthan KM, Anitha N, Krupaa J MS. Ameloblastoma. *J Pharm Bioallied Sci* x; Apr;7(Supp.
 18. Kim J, Nam E, Yoon S. Conservative management (marsupialization) of unicystic ameloblastoma: literature review and a case report. *Maxillofac Plast Reconstr Surg* 2017; 39: 1–6.
 19. Mendenhall WM, Werning JW, Fernandes R, et al. Ameloblastoma. *Am J Clin Oncol*; 30, <https://journals.lww.com/amjclinicaloncology/fulltext/2007/12000/ameloblastoma.13.aspx> (2007).
 20. Shepard JW, Thawley SE. Localization of upper airway collapse during sleep in patients with obstructive sleep apnea. *Am Rev Respir Dis* 1990; 141: 1350–1355.
 21. Kreppel M, Zöller J. Ameloblastoma—Clinical, radiological, and therapeutic findings. *Oral Dis* 2018; 24: 63–66.
 22. Oomens MAEM, van der Waal I. Epidemiology of ameloblastomas of the

- jaws; A report from the Netherlands. *Med Oral Patol Oral y Cir Bucal* 2014; 19: e581–e583.
23. Ruslin M, Hendra F, Vojdani A, et al. The Epidemiology, Treatment and Complication of Ameloblastoma in East-Indonesia: 6 Years Retrospective Study. *Med Oral Patol Oral Cir Bucal* 2018; 1: 54–58.
 24. Toprani SM, Kelkar Mane V. Role of DNA damage and repair mechanisms in uterine fibroid/leiomyomas: a review. *Biol Reprod* 2021; 104: 58–70.
 25. Soluk-Tekkebay M, Wright JM. The World Health Organization Classification of Odontogenic Lesions: A Summary of the Changes of the 2017 (4th) Edition. *J Istanbul Univ Fac Dent* 2017; 51: 1–18.
 26. Au SW, Li KY, Choi WS, et al. Risk factors for recurrence of ameloblastoma: a long-term follow-up retrospective study. *Int J Oral Maxillofac Surg* 2019; 48: 1300–1306.
 27. Gardner DG, Corio RL. Plexiform unicystic ameloblastoma: A variant of ameloblastoma with a low-recurrence rate after enucleation. *Cancer* 1984; 53: 1730–1735.
 28. Isomura ET, Okura M, Ishimoto S, et al. Case report of extralingival peripheral ameloblastoma in buccal mucosa. *Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology* 2009; 108: 577–579.
 29. Philipsen HP, Reichart PA, Nikai H, et al. Peripheral ameloblastoma: biological profile based on 160 cases from the literature. *Oral Oncol* 2001; 37: 17–27.
 30. Feranasari AAIA, Epsilawati L, Pramanik F. Laporan Kasus Fitur Radiografis Ameloblastoma pada CBCT dan Panoramik. *J Kedokt Gigi Univ Padjadjaran* 2020; 32: 47–51.
 31. Ranchod S, Titinchi F, Behardien N, et al. Ameloblastoma of the mandible: Analysis of radiographic and histopathological features. *J Oral Med Oral Surg* 2021; 27: 1–8.
 32. Robinson L, Martinez MG. Unicystic ameloblastoma. A prognostically distinct entity. *Cancer* 1977; 40: 2278–2285.
 33. Leider AS, Eversole LR, Barkin ME. Cystic ameloblastoma: a

- clinicopathologic analysis. *Oral surgery, oral Med oral Pathol* 1985; 60: 624–630.
34. Toprani SM. DNA damage and repair scenario in ameloblastoma. *Oral Oncol* 2020; 108: 104804.
 35. Brown NA, Betz BL. Ameloblastoma: a review of recent molecular pathogenetic discoveries. *Biomark Cancer* 2015; 7: BIC-S29329.
 36. Sciubba JJ, Eversole LR, Slootweg PJ, et al. World Health Organization Classification Head and Neck Tumours.
 37. Fan K, Andrews BT, Tabit CJ, et al. The Sarnat studies in craniofacial biology. *J Craniofac Surg* 2012; 23: 37–43.
 38. Heikinheimo K, Kurppa KJ, Elenius K. Novel targets for the treatment of ameloblastoma. *J Dent Res* 2015; 94: 237–240.
 39. Hupp J. Contemporary Oral and Maxillofacial Surgery.
 40. Gupta RJ, Kademani D, Liu SY-C. Upper airway (hypoglossal nerve) stimulation for treatment of obstructive sleep apnea. *Atlas Oral Maxillofac Surg Clin North Am* 2019; 27: 53–58.
 41. Giraddi GB, Arora K, Saifi AM. Ameloblastoma: A retrospective analysis of 31 cases. *J Oral Biol Craniofacial Res* 2017; 7: 206–211.
 42. Toppo S, Tajrin A, Al'amri M. Penatalaksanaan reseksi mandibula dengan pemasangan plat AO pada kasus ameloblastoma. *Makassar Dent J* 2014; 3: 1–9.
 43. Chai KS, Omar FH, Saad AZM, et al. A 20-year experience of immediate mandibular reconstruction using free fibula osteocutaneous flaps following ameloblastoma resection: Radical resection, outcomes, and recurrence. *Arch Plast Surg* 2019; 46: 426–432.
 44. Zhu J, Yang Y, Li W. Assessment of quality of life and sociocultural aspects in patients with ameloblastoma after immediate mandibular reconstruction with a fibular free flap. *Br J Oral Maxillofac Surg* 2014; 52: 163–167.
 45. Diener E, Suh EM, Lucas RE, et al. Subjective well-being: Three decades of progress. *Psychol Bull* 1999; 125: 276.

46. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. *N Engl J Med* 1996; 334: 835–840.
47. Hawkes AL, Patrao TA, Ware R, et al. Predictors of physical and mental health-related quality of life outcomes among myocardial infarction patients. *BMC Cardiovasc Disord* 2013; 13: 1–9.
48. Group Whoq. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). *Qual life Res* 1993; 2: 153–159.
49. Szabo S. The World Health Organisation Quality of life (WHOQOL) assesment instrument. *Qual life pharmacoeconomics Clin trials* 1996; 355–362.
50. Rogers SN, Monssen C, Humphris GM, et al. Which Head and Neck Cancer Patients Are Most at Risk of High Levels of Fear of Cancer Recurrence. *Front Psychol* 2021; 12: 671366.
51. Li W, Yang Y, Xu Z, et al. Assessment of quality of life of patients with oral cavity cancer who have had defects reconstructed with free anterolateral thigh perforator flaps. *Br J Oral Maxillofac Surg* 2013; 51: 497–501.
52. Moons P, Marquet K, Budts W, et al. Validity, reliability and responsiveness of the " Schedule for the Evaluation of Individual Quality of Life–Direct Weighting"(SEIQoL-DW) in congenital heart disease. *Health Qual Life Outcomes* 2004; 2: 1–8.
53. Fadda G, Jirón P. Quality of life and gender: a methodology for urban research. *Environ Urban* 1999; 11: 261–270.
54. Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. *Cancer* 2008; 113: 1911–1932.
55. Angelo AR, Medeiros AC de, Biasi R. Qualidade de vida em pacientes com câncer na região de cabeça e pescoço. *Rev Odontol UNESP* 2010; 39: 1–7.
56. Yeh S-A. Radiotherapy for head and neck cancer. In: *Seminars in plastic surgery*. © Thieme Medical Publishers, 2010, pp. 127–136.
57. Noghaani M, Asgharpour A, Kermani M, et al. The quality of life and its relation with social capital in the city of Mashhad. *J Soc Sci Ferdowsi Univ*

Mashhad; 2.

58. Wahl AK, Rustøen T, Rokne B, et al. The complexity of the relationship between chronic pain and quality of life: a study of the general Norwegian population. *Qual Life Res* 2009; 18: 971–980.
59. World Health Organization (WHO). Constitution of the world health organization.
60. Yang W, Zhao S, Liu F, et al. Health-related quality of life after mandibular resection for oral cancer: Reconstruction with free fibula flap. *Med Oral Patol Oral Cir Bucal* 2014; 19: 414–418.
61. Myers D. Community-relevant measurement of quality of life: A focus on local trends. *Urban Aff Q* 1987; 23: 108–125.
62. O'Connor RE. *Issues in the measurement of health-related quality of life*. National Centre for Health Program Evaluation Melbourne, 1993.
63. Whoqol Group. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. *Soc Sci Med* 1995; 41: 1403–1409.
64. Gomes EPA de A, Aranha AMF, Borges AH, et al. Head and Neck Cancer Patients' Quality of Life: Analysis of Three Instruments. *J Dent (Shiraz, Iran)* 2020; 21: 31–41.
65. Andriyani D. Hubungan Merokok dengan Kebersihan Gigi dan Mulut Siswa SMK di Bandar Lampung. *J Ilm Keperawatan Sai Betik* 2018; 13: 83–89.
66. Yulianita ME, Dewi C. Hubungan Kebiasaan Merokok Dengan Kejadian Karies Gigi Di Dusun Bilaji Kecamatan Barombong Kabupaten Gowa. *J Mitrasedhat* 2020; 10: 193–201.
67. Bergamasco VD, Marta GM, Kowalski LP CA. Epidemiological profile of head and neck cancer in the State of São Paulo. *Rev Bras Cir Cabeça Pescoço*; 37: 15–19.
68. Hong J, Yun P-Y, Chung I-H, et al. Long-term follow up on recurrence of 305 ameloblastoma cases. *Int J Oral Maxillofac Surg* 2007; 36: 283–288.
69. Rusdiana R, Sandini SU, Vitria EE, et al. Profile of Ameloblastoma from a Retrospective Study in Jakarta, Indonesia. *J Dent Indones* 2011; 18: 27–32.

70. Effiom OA, Ogundana OM, Akinshipo AO, et al. Ameloblastoma: current etiopathological concepts and management. *Oral Dis* 2018; 24: 307–316.
71. Marwin M, Perwitasari DA, Purba FD, et al. Hubungan Karakteristik Terhadap Kualitas Hidup Pasien Kanker Payudara yang Menjalani Kemoterapi di RSUP Dr. Kariadi Semarang. *J Sains dan Kesehat* 2021; 3: 505–512.
72. Almutairi KM, Mansour EA, Vinluan JM. A cross-sectional assessment of quality of life of breast cancer patients in Saudi Arabia. *Public Health* 2016; 136: 117–125.
73. Ahlem B, Wided A, Amani L, et al. Study of Ki67 and CD10 expression as predictive factors of recurrence of ameloblastoma. *Eur Ann Otorhinolaryngol Head Neck Dis* 2015; 132: 275–279.
74. Yew CC, Ismail RB, Md Zin MNB, et al. Modified conservative management of mandibular ameloblastoma: a 13-year experience in a Malaysian tertiary care centre. *Oral Surg* 2020; 13: 230–236.
75. Ajila V, Hegde S. Ameloblastomas vs recurrent ameloblastomas: A systematic review. *J Oral Med Oral Surg* 2022; 28: 1–8.
76. Cadavid AMH, Araujo JP, Coutinho-Camillo CM, et al. Ameloblastomas: current aspects of the new WHO classification in an analysis of 136 cases. *Surg Exp Pathol* 2019; 2: 4–9.
77. Hresko A, Burtyn O, Pavlovskiy L, et al. Controversies in ameloblastoma management: evaluation of decision making, based on a retrospective analysis. *Med Oral Patol Oral Cir Bucal* 2021; 26: e181.
78. Hertog D, Schulten EAJM, Leemans CR, et al. Management of recurrent ameloblastoma of the jaws; a 40-year single institution experience. *Oral Oncol* 2011; 47: 145–146.
79. Masood M, Newton T, Bakri NN, et al. The relationship between oral health and oral health related quality of life among elderly people in United Kingdom. *J Dent* 2017; 56: 78–83.
80. Gunardi I, Trisakti U. Quality of life post ameloblastoma treatment : a meta analysis.

81. Dholam KP, Dugad JA, Sadashiva KM. Impact of oral rehabilitation on patients with head and neck cancer: A study using the Liverpool Oral Rehabilitation Questionnaire and the Oral Health Impact Profile-14. *J Prosthet Dent* 2017; 117: 559–562.
82. Rogers SN, Scott J, Chakrabati A, et al. The patients' account of outcome following primary surgery for oral and oropharyngeal cancer using a 'quality of life' questionnaire. *Eur J Cancer Care (Engl)* 2008; 17: 182–188.
83. Conforte JJ, Alves CP, Sánchez M delP. R, et al. Impact of trauma and surgical treatment on the quality of life of patients with facial fractures. *Int J Oral Maxillofac Surg* 2016; 45: 575–581.
84. Gandjalikhan-Nassab S-A-H, Samieirad S, Vakil-Zadeh M, et al. Depression and anxiety disorders in a sample of facial trauma: A study from Iran. *Med Oral Patol Oral Cir Bucal* 2016; 21: e477-82.
85. Lewandowski B, Szeliga E, Czenczek-Lewandowska E, et al. Comparison of oral-health-related quality of life in patients in the short- and long-term period following lower-facial injury and fractures – Preliminary report. *Dent Med Probl* 2018; 55: 57–62.
86. Au SW, Li KY, Choi WS, et al. Risk factors for recurrence of ameloblastoma: a long-term follow-up retrospective study. *Int J Oral Maxillofac Surg* 2019; 48: 1300–1306.
87. Suksri S, Chinkruea C. Large buccal soft tissue recurrence of ameloblastoma following conservative treatment in paediatric patient: a case report. *Int J Oral Maxillofac Surg* 2015; 44: e292.
88. Laborde A, Nicot R, Wojcik T, et al. Ameloblastoma of the jaws: Management and recurrence rate. *Eur Ann Otorhinolaryngol Head Neck Dis* 2017; 134: 7–11.
89. Algave DP. Quality of Life in Total Laryngectomy Patients : an Analysis of Different Assessment Tools. *Cefac* 1993; 17: 58–70.

LAMPIRAN

Lampiran 1. Etika Penelitian



KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN GIGI
RUMAH SAKIT GIGI DAN MULUT
KOMITE ETIK PENELITIAN KESEHATAN
Sekretariat : Lantai 2, Gedung Lama RSGM Unhas
JL.Kandea No. 5 Makassar



Contact Person: drg. Muhammad Iqbal, Sp.Prost/Nur Aedah AR TELP. 08134297101/08114919191

REKOMENDASI PERSETUJUAN ETIK

Nomor: 0079/PL.09/KEFK FKG-RSGM UNHAS/2023

Tanggal: 16 Mei 2023

Dengan ini menyatakan bahwa protokol dan dokumen yang berhubungan dengan protokol berikut ini telah mendapatkan persetujuan etik:

No. Protokol	UH 17120820	No Protokol Sponsor	
Peneliti Utama	drg. Ochtavianus Kano T	Sponsor	Pribadi
Judul Peneliti	Kualitas Hidup Pasien penderita <i>Ameloblastoma</i> Setelah Perawatan Radikal di Rumah sakit Pendidikan dan Jejaring		
No. Versi Protokol	1	Tanggal Versi	09 Mei 2023
No. Versi Protokol		Tanggal Versi	
Tempat Penelitian	Rumah sakit Utama dan Rumah sakit jejaring di Kota Makassar		
Dokumen Lain			
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard	Masa Berlaku 16 Mei 2023-16 Mei 2024	Frekuensi Review Lanjutan
Ketua Komisi Etik Penelitian	Nama: Dr. drg. Marhamah, M.Kes	Tanda Tangan 	Tanggal
Sekretaris Komisi Etik Penelitian	Nama: drg. Muhammad Iqbal, Sp.Prost	Tanda Tangan 	Tanggal

Kewajiban peneliti utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum diimplementasikan
- Menyerahkan laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan lapor SUSAR dalam 72 jam setelah peneliti utama menerima laporan.
- Menyerahkan laporan kemajuan (*progress report*) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah.
- Menyerahkan laporan akhir setelah penelitian berakhir.
- Melaporkan penyimpangan dari protokol yang disetujui (*protocol deviation/violation*)
- Mematuhi semua aturan yang berlaku.

Lampiran 2. Analisis SPSS

jenis kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	13	59.1	59.1	59.1
	Perempuan	9	40.9	40.9	100.0
	Total	22	100.0	100.0	

UsiaTahun

		Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	14	1	4,5	4,5	4,5	
	19	1	4,5	4,5	9,1	
	20	1	4,5	4,5	13,6	
	26	1	4,5	4,5	18,2	
	28	1	4,5	4,5	22,7	
	30	1	4,5	4,5	27,3	
	31	2	9,1	9,1	36,4	
	32	1	4,5	4,5	40,9	
	35	1	4,5	4,5	45,5	
	42	1	4,5	4,5	50,0	
	43	1	4,5	4,5	54,5	
	44	1	4,5	4,5	59,1	
	47	1	4,5	4,5	63,6	
	50	3	13,6	13,6	77,3	
	51	1	4,5	4,5	81,8	
	52	1	4,5	4,5	86,4	
	53	1	4,5	4,5	90,9	
	58	2	9,1	9,1	100,0	
	Total		22	100,0	100,0	

KTG_umur

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<=30	10	27.3	27.3	47.3
	>30	12	72.7	72.7	100.0
	Total	22	100.0	100.0	

TingkatPendidikan

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	S1	9	40.9	40.9	40.9
	SMA/SMP	13	59.1	59.1	100.0
	Total	22	100.0	100.0	

Diagnosa

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Anterior Mandibula	3	13.6	13.6	13.6
	Mandibula Dextra	11	50.0	50.0	63.6
	Mandibula Sinistra	8	36.4	36.4	100.0
	Total	22	100.0	100.0	

*** jeniskelamin Crosstabulation**

Count

		jeniskelamin		Total
		1	2	
ktguwqolfix	Sangat Baik	13	9	22
Total		13	9	22

ktguwqolfix * KTG_umur Crosstabulation

Count

		KTG_umur		Total
		<38	>38	
ktguwqolfix	Sangat Baik	10	12	22
Total		10	12	22

ktguwqolfix * Ktg_radio Crosstabulation

Count

		Ktg_radio		Total
		Konvensional	Unicystic	
ktguwqolfix	Sangat Baik	18	4	22
Total		18	4	22

ktguwqolfix * ktg_histo Crosstabulation

Count

		ktg_histo		Total
		Acanthomatous/ Follicular	Plexiform/Granular	
ktguwqolfix	Sangat Baik	14	8	22
Total		14	8	22

ktguwqolfix * jeniskelamin Crosstabulation

		jeniskelamin		Total	
		1	2		
ktguwqolfix	Sangat Baik	Count	13	9	22
		% within ktguwqolfix	59,1%	40,9%	100,0%
Total		Count	13	9	22
		% within ktguwqolfix	59,1%	40,9%	100,0%

ktguwqolfix * KTG_umur Crosstabulation

		KTG_umur		Total	
		<38	>38		
ktguwqolfix	Sangat Baik	Count	6	16	22
		% within ktguwqolfix	27.3%	72.7%	100,0%
Total		Count	10	12	22
		% within ktguwqolfix	27.3%	72.7%	100,0%

ktguwqolfix * Ktg_radio Crosstabulation

		Ktg_radio		Total	
		Konvensional	Unicystic		
ktguwqolfix	Sangat Baik	Count	18	4	22
		% within ktguwqolfix	81,8%	18,2%	100,0%
Total		Count	18	4	22
		% within ktguwqolfix	81,8%	18,2%	100,0%

ktguwqolfix * ktg_histo Crosstabulation

		ktg_histo		Total	
		Acanthomatous/ Follicular	Plexiform/Granular		
ktguwqolfix	Sangat Baik	Count	14	8	22
		% within ktguwqolfix	63,6%	36,4%	100,0%
Total		Count	14	8	22
		% within ktguwqolfix	63,6%	36,4%	100,0%

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Skorafter & Skorgood	22	-,351	,109